Device Trial Radar · NCT05183009
eXciteOSA for Treatment of Mild Obstructive Sleep Apnea
Last checked: Nov 20, 2026Latest source record: Dec 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
102
Actual
Start
Jan 17, 2022
Primary completion
Dec 31, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Signifier Medical TechnologiesNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 10, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the efficacy of the eXciteOSA device amongst a sample of patients with mild OSA. The study is a multi-center, prospective, open-label, randomized, parallel-arm trial of eXciteOSA versus no-therapy for six weeks. Up to 200 participants will be enrolled, in order to randomized n=102.
Conditions
- Sleep Apnea, Obstructive
Interventions
eXciteOSADevice
eXciteOSA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Respiratory event indexTime frame: Six weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Sleep Disorders Center of Alabama
Birmingham, Alabama
Delta Waves
Colorado Springs, Colorado
Florida Lung & Sleep Associates
Lehigh Acres, Florida
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.